Steroid manufacturers Sterling S.r.l., located in Perugia, Italy, is now producing APIs for respiratory delivery using particle engineering technology supplied by Prosonix. A two-year collaboration between the two companies has resulted in a retrofit of existing Sterling equipment at the company’s FDA-approved facility.
The Prosonix crystallization technology allows for control of particle size, shape, and crystallinity, allowing for the manufacture of particles suitable for inhalation without micronization. Sterling CEO Simone Ferlin commented, “By integrating the Prosonix technology, together we have been able to introduce novel, high performance, particle engineered API into the respiratory market to support an unmet, pressing and growing industry need. This symbiotic partnership provides significant differentiation for both Sterling and Prosonix, but most importantly provides Clients with the surety and quality of steroids that delivers the optimum solution for the complex respiratory challenges.”
Read the Prosonix/Sterling press release.
